Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cergutuzumab amunaleukin plus atezolizumab dose-escalation study in advanced solid tumors
NL-OMON46963Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cergutuzumab amunaleukin and atezolizumab in Nonhematologic neoplasms, sponsored by Roche. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Started Jan 2015; status: active, not recruiting.
02
Drugs
cergutuzumab amunaleukinatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46963.